Evidence map›Paper›PMID 35284802›Full record

ArticleHemaSphere2022

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

Nadine Kutsch, Christian Pallasch, Eugen Tausch, Volkmar Böhme, Matthias Ritgen, Rüdiger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 2 countries.

Nadine KutschDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Christian PallaschDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
Eugen TauschDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Volkmar BöhmeOncology Lerchenfeld Clinic, Hamburg, Germany.
Matthias RitgenDepartment of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
Rüdiger LierschGemeinschaftspraxis für Hämatologie und Onkologie, Clemenshospital Münster, Düesbergweg, Germany.
Alexander WackerDepartment of Internal Medicine I, Klinikum am Steinenberg, Reutlingen, Germany.
Georg JacobsPraxis Fuer Onkologie, Saarbrücken, Germany.
Ralf Ulrich TrappeDepartment of Hematology and Oncology, DIAKO Hospital Bremen, Germany.
Peter DregerDepartment of Medicine V, University Hospital Heidelberg, Germany.
Kirsten FischerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Anna-Maria FinkDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Shuyan ZhaiGilead Sciences, Inc., Foster City, California, USA.
Biao LiGilead Sciences, Inc., Foster City, California, USA.
Juliane M JürgensmeierGilead Sciences, Inc., Foster City, California, USA.
Nishanthan RajakumaraswamyGilead Sciences, Inc., Foster City, California, USA.
Pankaj BhargavaGilead Sciences, Inc., Foster City, California, USA.
Michael HallekDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Barbara F EichhorstDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
Gilead Sciences (United States) · USUniversity of Cologne · DEUniversität Ulm · DEUniversity Hospital Cologne · DEClemenshospital Münster · DEDIAKO · DEHeidelberg University · DEKiel University · DEKreiskliniken Reutlingen · DEPraxis für Hämatologie und Onkologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35284802
PMCPMC8906452
OpenAlexW4220734819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.